Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6872992 | 1.00 | PRCP (0.39) | PRCPNFKB1NFKB2RELABTK | |
| SCHEMBL28232408 | 0.92 | PRCP (0.43) | PRCPNFKB1NFKB2RELABTK | |
| SCHEMBL7299117 | 0.92 | PRCP (0.43) | PRCPNFKB1NFKB2RELABTK | |
| SCHEMBL373560 | 0.92 | PRCP (0.43) | PRCPNFKB1NFKB2RELABTK | |
| SCHEMBL4630085 | 0.90 | SCN9A (0.39) | PRCPNFKB1NFKB2RELABTK | |
| SCHEMBL3610491 | 0.90 | SCN9A (0.39) | PRCPNFKB1NFKB2RELABTK | |
| SCHEMBL4696693 | 0.83 | SPHK1 (0.38) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL8554595 | 0.83 | NFKB1 (0.35) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL8554345 | 0.83 | NFKB1 (0.35) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL16857339 | 0.82 | CHRM2 (0.36) | NFKB1NFKB2RELABTKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| EP-1919864-A2 | FAP INHIBITORS | Ferring B.V. (NL) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | PRCP 64/4885NFKB1 1453/4885NFKB2 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.